We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 101.50 | 98.00 | 105.00 | 101.50 | 101.50 | 101.50 | 7,401 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 24k | -17.01M | -0.2722 | -3.73 | 63.41M |
From May 2022 to May 2024
TIDMCEL
RNS Number : 3678Q
Celadon Pharmaceuticals PLC
27 June 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Result of Annual General Meeting
London, UK, 27 June 2022 : Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development and supply of natural, cannabis-based medicines, announces that at its Annual General Meeting held today, all resolutions were duly passed.
Full details of the poll results will shortly be set out on the Company's website , along with Celadon's recent Business Update, which was published on 22 June 2022 .
Enquiries:
Celadon Pharmaceuticals Plc James Short Via Powerscourt Arthur Wakeley Canaccord Genuity Limited (Nominated Adviser and Broker) Andrew Potts / Patrick Dolaghan +44 (0) 20 7523 8000 Powerscourt Group Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0) 20 7250 1446 / celadon@powerscourt-group.com Ibrahim Khalil
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of natural cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence for the legal cultivation of high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns an MHRA conditionally approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.
For further information please visit our website www.celadonpharma.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGBKOBKOBKDCAB
(END) Dow Jones Newswires
June 27, 2022 13:15 ET (17:15 GMT)
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
